Biofrontera (BFRI) director awarded 20,000-share employee stock option grant

Rhea-AI Filing Summary

Biofrontera Inc. director John J. Borer III received an employee stock option grant on March 4, 2026. The award covers options to purchase 20,000 shares, reported at a price of $0.00 per share as a derivative security grant. According to the terms, the option vests in twelve equal monthly installments beginning on April 4, 2026, so the director earns the right to exercise portions of the option gradually over one year.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BORER JOHN J III

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Employee stock option (right to buy) — 20,000 shares (Direct)

Footnotes (1)

1. The option vests in twelve equal monthly instalments beginning on April 4, 2026. Options with different terms are not included.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BORER JOHN J III

(Last) (First) (Middle)

660 MAIN STREET

FIRST FLOOR

(Street)

WOBURN MA 01801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biofrontera Inc. [ BFRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$0.9	03/04/2026		A		20,000		(1)	03/04/2036	Common Stock	20,000	$0	20,000(2)	D

Explanation of Responses:

1. The option vests in twelve equal monthly instalments beginning on April 4, 2026.

2. Options with different terms are not included.

	/s/ Daniel Hakansson, Attorney-in-fact for John J. Borer	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Biofrontera Inc. (BFRI) director John J. Borer III report on this Form 4?

He reported an employee stock option grant for 20,000 shares of Biofrontera Inc. common stock. The option was granted on March 4, 2026, as a derivative security and is held directly by him as reported in the filing.

How many Biofrontera Inc. (BFRI) options were granted to the director?

The director received an option for 20,000 shares of Biofrontera Inc. common stock. This entire amount represents a new grant, with 20,000 options reported as beneficially owned following the transaction in the Form 4.

When do the Biofrontera Inc. (BFRI) options granted to the director start vesting?

The granted options begin vesting on April 4, 2026. The vesting schedule is spread over twelve equal monthly installments, meaning portions of the 20,000-share option become exercisable each month over the following year.

What is the reported exercise price of the Biofrontera Inc. (BFRI) options?

The Form 4 lists a transaction price of $0.00 per share for the employee stock option. This price reflects how the grant is reported as a derivative award, rather than a market purchase or sale of common stock.

Is this Biofrontera Inc. (BFRI) Form 4 a purchase or a grant of options?

This Form 4 reflects a grant or award acquisition of options, not an open-market stock purchase. The transaction code “A” and description specify it as a grant, award, or other acquisition of derivative securities.

How many Biofrontera Inc. (BFRI) derivative securities does the director own after this grant?

After the reported transaction, the director beneficially owns 20,000 employee stock options according to the filing. These options vest over twelve months starting April 4, 2026, based on the disclosed vesting schedule.